On the afternoon of September 24, Mr. Do Tuan Dat, Chairman of the No. 1 Vaccine and Biological Products Company Limited (VABIOTECH), said that the company has successfully produced a batch of vaccines. Sputnik VU vaccine first in Vietnam.
This batch of Covid-19 vaccine has been analyzed and evaluated by the Russian side to meet regulatory requirements. This event will help Vietnamese people soon access a source of quality vaccines, contributing to the fight against the Covid-19 epidemic.
VABIOTECH closed vials of Sputnik V vaccine from semi-finished products in July. The scale of processing and sealing is 5 million doses/month, expected to increase to 100 million doses/year. The company built a factory to receive and transfer technology for producing vaccines for Sputnik V.
Producing Sputnik-V vaccine from semi-finished materials in Vietnam – Photo: Long Pham
The first batch of 30,000 doses of vaccine was packed by VABIOTECH, of which 10,000 samples were sent to Russia for quality control. After receiving a reply from Russia, Mr. Dat said that VABIOTECH is working with relevant units to apply for factory permits for these batches.
“In this September, the company will carry out procedures to import semi-finished products of Sputnik V vaccine to Vietnam to quickly pack and pack this vaccine in Vietnam in order to proactively supply Sputnik-V vaccine. in Vietnam,” said Mr. Dat.
The Sputnik V vaccine was conditionally approved by the Ministry of Health for urgent needs in the prevention of the Covid-19 epidemic in March 2021. This vaccine is produced by JSC Generium – Russian Federation. According to the latest guidelines of the Ministry of Health, this is a vaccine not for use in pregnant and lactating women.
Mr. Dat said that VABIOTECH also promotes the application unit of the Sputnik Light vaccine to quickly register for this vaccine, after which VABIOTECH will discuss with the supplier in Russia to pack the vaccine tube. this in Vietnam. Unlike other vaccines, Sputnik Light only requires a single dose.
According to the results of a clinical trial published in the journal “The Lancet”, the Sputnik V vaccine was 91.6% effective. Particularly for volunteers over 60 years old, this rate is 91.8%. After injection, 98% of the volunteers had antibodies against the SARS-CoV-2 virus.
Data on the incidence of SARS-CoV-2 infection in people vaccinated with Sputnik V vaccine from December 5, 2020 to March 31, 2021 in Russia, shows that the protective effect of Sputnik V is 97 ,6%.